CHENIX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHENIX (CHENIX).
Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by blocking the reuptake of serotonin at the synaptic cleft.
| Metabolism | Hepatic via CYP2D6 (N-demethylation to norfluoxetine) and CYP3A4; norfluoxetine is active and undergoes further metabolism. |
| Excretion | Primarily renal (70-80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for 20-30%. |
| Half-life | Terminal elimination half-life is approximately 22-28 hours in adults with normal renal function. This supports once-daily dosing; half-life prolongation in renal impairment requires dose adjustment. |
| Protein binding | Approximately 60-70% bound to serum albumin primarily; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 1.2-2.0 L/kg, indicating extensive tissue binding and distribution beyond plasma compartment. |
| Bioavailability | Oral bioavailability of immediate-release formulation is 30-40% due to first-pass metabolism; extended-release formulation bioavailability is 25-35%. |
| Onset of Action | Oral: 30-60 minutes to detectable serum concentrations; clinical effect (antianginal) observed within 1-2 hours. Intravenous: immediate onset within minutes. |
| Duration of Action | Duration of antianginal effect is 8-12 hours after oral administration; extended-release formulations provide 12-24 hour coverage. Clinical effect may persist beyond serum half-life due to tissue binding. |
| Molecular Weight | 412.32 |
CHENIX: 20 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | eGFR ≥60 mL/min: no adjustment; eGFR 30-59: 10 mg once daily; eGFR <30 or dialysis: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 10 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Safety and efficacy not established; use not recommended. |
| Geriatric use | Start at 10 mg once daily; titrate based on response and tolerability. |
| 1st trimester | Contraindicated due to risk of teratogenicity (animal studies show fetal abnormalities; no adequate human studies). |
| 2nd trimester | Contraindicated due to potential fetal harm (may interfere with fetal development). |
| 3rd trimester | Contraindicated due to risk of neonatal toxicity (e.g., kernicterus in newborns). |
Clinical note
Comprehensive clinical and safety monograph for CHENIX (CHENIX).
| Placental transfer | Readily crosses placenta (animal studies show placental transfer; human data limited but presumed extensive due to molecular weight and high protein binding). |
| Breastfeeding | Excreted into breast milk in low concentrations; however, due to potential for serious adverse reactions (e.g., kernicterus in neonates), breastfeeding is not recommended during therapy and for 2 weeks after last dose. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
| Serious Effects |
PregnancyBreastfeedingSevere hepatic impairmentHypersensitivity to CHENIX or any excipientConcurrent use with drugs known to cause photosensitivity
| Precautions | Suicidality risk in young patients, Serotonin syndrome, Drug interactions with MAOIs, QT prolongation, Bleeding risk, Activation of mania/hypomania |
| Food/Dietary | Avoid high-fat meals as they may reduce drug absorption. Take with food to minimize gastrointestinal upset. Do not consume grapefruit juice, which may alter drug metabolism. Maintain a balanced diet low in cholesterol as part of gallstone management. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | CHENIX is contraindicated in pregnancy due to high teratogenic risk. First trimester exposure causes craniofacial defects (cleft palate, micrognathia), neural tube defects, and cardiac malformations. Second and third trimester exposure leads to intrauterine growth restriction, oligohydramnios, and neonatal renal impairment. No safe gestational window exists. |
| Fetal Monitoring | If inadvertent exposure occurs, monitor maternal renal function (serum creatinine, BUN), liver enzymes, and complete blood count. Fetal monitoring includes serial ultrasound for growth parameters, amniotic fluid index, and targeted fetal anatomy survey. Neonatal assessment for renal function and electrolyte status is required postpartum. |
| Fertility Effects | CHENIX has been associated with reversible impairment of spermatogenesis in males (oligospermia, decreased motility) and anovulatory cycles in females due to hypothalamic-pituitary-gonadal axis suppression. Effects resolve within 3–6 months of discontinuation. Preconception counseling recommended for both sexes. |
| Clinical Pearls | Chenix is not a recognized drug; ensure correct spelling. For presumed misspelling of 'Chenix' as a trade name, no data exists; consult official sources. If referring to 'Chenodiol' (Chenodeoxycholic acid), monitor LFTs and serum cholesterol. Use with caution in hepatobiliary disease. May dissolve radiolucent gallstones in selected patients with functioning gallbladder. |
| Patient Advice | Take this medication exactly as prescribed, usually twice daily with meals. · You may need periodic blood tests to monitor liver function and cholesterol levels. · Report any signs of liver problems: jaundice, dark urine, severe abdominal pain. · This drug may cause diarrhea; contact your doctor if diarrhea becomes severe or persistent. · Do not take antacids containing aluminum or bile acid sequestrants (e.g., cholestyramine) within 2 hours of this medication. · Use effective contraception if applicable; discuss pregnancy planning with your doctor. |